Objective: To systematically analyze the revisions content and technological development trends of microbiological standards in the Chinese Pharmacopoeia (ChP) 2025 Edition, and explore its novel requirements in risk-based pharmaceutical product lifecycle management.
Methods: A comprehensive review was conducted on 26 microbiological-related standards to summarize the revision directions and scientific implications from perspectives including the revision overview, international harmonization of microbiological standards, risk-based quality management system, and novel tools and methods with Chinese characteristics.
Results: The ChP 2025 edition demonstrates three prominent features in microbiological-related standards: enhanced international harmonization, introduced emerging molecular biological technologies, and established a risk-based microbiological quality control system.
Conclusion: The new edition of the Pharmacopoeia has systematically constructed a microbiological standard system, which significantly improves the scientificity, standardization and applicability of the standards, providing a crucial support for advancing the microbiological quality control in pharmaceutical industries of China.

Objective:To investigate the therapeutic effectiveness and related factors of fertility preservation therapy(referred to as conservation therapy)using Levonorgestre-releasing intrauterine system(LNG-IUS)com-bined with Metformin in patients with atypical endometrial hyperplasia and early endometrial cancer.Methods:A retrospective analysis was conducted on the clinical data of 41 patients with atypical endometrial hyperplasia and 11 patients with early endometrial cancer who required fertility preservation therapy and admitted to Shenyang Women and Children's Hospital from January 1,2015 to December 30,2021.According to different treatment methods,they were divided into a study group(26 cases,LNG-IUS+metformin)and a control group(26 cases,high efficiency progesterone+metformin).Regularly review endometrial pathology and analyze the differences in complete remission rate,recurrence rate,and pregnancy outcomes between the two groups.Univariate Logistic regression was used to analyze the factors affecting complete remission,recurrence,and pregnancy outcomes in those patients.Results:There was no statistically significant difference in general clinical data between the two groups(P＞0.05).Compared with the control group,the study group had higher complete remission rate,shorter average complete remission time,less recurrence rate,and higher live birth rate,with a statistically significant be-tween the two groups(P＜0.05).Logistic regression analysis found that body mass index(BMI)≥30 kg/m2was a risk factor for complete remission(P＜0.05);BMI ≥30 kg/m2 and patients with diabetes or insulin resistance were the risk factors for recurrence after treatment(P＜0.05);BMI≥30 kg/m2 and diseases associated with fe-male reproductive system were the risk factors for pregnancy after preserving fertility therapy(P＜0.05).Conclu-sions:LNG-IUS combined with metformin has a more satisfactory therapeutic effect and pregnancy outcomes,compared to high efficiency progesterone combined with metformin in preserving fertility therapy.At the same time,BMI＜30 kg/m2 can increase the complete remission rate,reduce the recurrence rate after cure,and in-crease the pregnancy rate after preserving fertility therapy.

Objective:To investigate the therapeutic effectiveness and related factors of fertility preservation therapy(referred to as conservation therapy)using Levonorgestre-releasing intrauterine system(LNG-IUS)com-bined with Metformin in patients with atypical endometrial hyperplasia and early endometrial cancer.Methods:A retrospective analysis was conducted on the clinical data of 41 patients with atypical endometrial hyperplasia and 11 patients with early endometrial cancer who required fertility preservation therapy and admitted to Shenyang Women and Children's Hospital from January 1,2015 to December 30,2021.According to different treatment methods,they were divided into a study group(26 cases,LNG-IUS+metformin)and a control group(26 cases,high efficiency progesterone+metformin).Regularly review endometrial pathology and analyze the differences in complete remission rate,recurrence rate,and pregnancy outcomes between the two groups.Univariate Logistic regression was used to analyze the factors affecting complete remission,recurrence,and pregnancy outcomes in those patients.Results:There was no statistically significant difference in general clinical data between the two groups(P＞0.05).Compared with the control group,the study group had higher complete remission rate,shorter average complete remission time,less recurrence rate,and higher live birth rate,with a statistically significant be-tween the two groups(P＜0.05).Logistic regression analysis found that body mass index(BMI)≥30 kg/m2was a risk factor for complete remission(P＜0.05);BMI ≥30 kg/m2 and patients with diabetes or insulin resistance were the risk factors for recurrence after treatment(P＜0.05);BMI≥30 kg/m2 and diseases associated with fe-male reproductive system were the risk factors for pregnancy after preserving fertility therapy(P＜0.05).Conclu-sions:LNG-IUS combined with metformin has a more satisfactory therapeutic effect and pregnancy outcomes,compared to high efficiency progesterone combined with metformin in preserving fertility therapy.At the same time,BMI＜30 kg/m2 can increase the complete remission rate,reduce the recurrence rate after cure,and in-crease the pregnancy rate after preserving fertility therapy.

Objective:To investigate the therapeutic effectiveness and related factors of fertility preservation therapy(referred to as conservation therapy)using Levonorgestre-releasing intrauterine system(LNG-IUS)com-bined with Metformin in patients with atypical endometrial hyperplasia and early endometrial cancer.Methods:A retrospective analysis was conducted on the clinical data of 41 patients with atypical endometrial hyperplasia and 11 patients with early endometrial cancer who required fertility preservation therapy and admitted to Shenyang Women and Children's Hospital from January 1,2015 to December 30,2021.According to different treatment methods,they were divided into a study group(26 cases,LNG-IUS+metformin)and a control group(26 cases,high efficiency progesterone+metformin).Regularly review endometrial pathology and analyze the differences in complete remission rate,recurrence rate,and pregnancy outcomes between the two groups.Univariate Logistic regression was used to analyze the factors affecting complete remission,recurrence,and pregnancy outcomes in those patients.Results:There was no statistically significant difference in general clinical data between the two groups(P＞0.05).Compared with the control group,the study group had higher complete remission rate,shorter average complete remission time,less recurrence rate,and higher live birth rate,with a statistically significant be-tween the two groups(P＜0.05).Logistic regression analysis found that body mass index(BMI)≥30 kg/m2was a risk factor for complete remission(P＜0.05);BMI ≥30 kg/m2 and patients with diabetes or insulin resistance were the risk factors for recurrence after treatment(P＜0.05);BMI≥30 kg/m2 and diseases associated with fe-male reproductive system were the risk factors for pregnancy after preserving fertility therapy(P＜0.05).Conclu-sions:LNG-IUS combined with metformin has a more satisfactory therapeutic effect and pregnancy outcomes,compared to high efficiency progesterone combined with metformin in preserving fertility therapy.At the same time,BMI＜30 kg/m2 can increase the complete remission rate,reduce the recurrence rate after cure,and in-crease the pregnancy rate after preserving fertility therapy.

Objective:To investigate the therapeutic effectiveness and related factors of fertility preservation therapy(referred to as conservation therapy)using Levonorgestre-releasing intrauterine system(LNG-IUS)com-bined with Metformin in patients with atypical endometrial hyperplasia and early endometrial cancer.Methods:A retrospective analysis was conducted on the clinical data of 41 patients with atypical endometrial hyperplasia and 11 patients with early endometrial cancer who required fertility preservation therapy and admitted to Shenyang Women and Children's Hospital from January 1,2015 to December 30,2021.According to different treatment methods,they were divided into a study group(26 cases,LNG-IUS+metformin)and a control group(26 cases,high efficiency progesterone+metformin).Regularly review endometrial pathology and analyze the differences in complete remission rate,recurrence rate,and pregnancy outcomes between the two groups.Univariate Logistic regression was used to analyze the factors affecting complete remission,recurrence,and pregnancy outcomes in those patients.Results:There was no statistically significant difference in general clinical data between the two groups(P＞0.05).Compared with the control group,the study group had higher complete remission rate,shorter average complete remission time,less recurrence rate,and higher live birth rate,with a statistically significant be-tween the two groups(P＜0.05).Logistic regression analysis found that body mass index(BMI)≥30 kg/m2was a risk factor for complete remission(P＜0.05);BMI ≥30 kg/m2 and patients with diabetes or insulin resistance were the risk factors for recurrence after treatment(P＜0.05);BMI≥30 kg/m2 and diseases associated with fe-male reproductive system were the risk factors for pregnancy after preserving fertility therapy(P＜0.05).Conclu-sions:LNG-IUS combined with metformin has a more satisfactory therapeutic effect and pregnancy outcomes,compared to high efficiency progesterone combined with metformin in preserving fertility therapy.At the same time,BMI＜30 kg/m2 can increase the complete remission rate,reduce the recurrence rate after cure,and in-crease the pregnancy rate after preserving fertility therapy.

Objective:To investigate the therapeutic effectiveness and related factors of fertility preservation therapy(referred to as conservation therapy)using Levonorgestre-releasing intrauterine system(LNG-IUS)com-bined with Metformin in patients with atypical endometrial hyperplasia and early endometrial cancer.Methods:A retrospective analysis was conducted on the clinical data of 41 patients with atypical endometrial hyperplasia and 11 patients with early endometrial cancer who required fertility preservation therapy and admitted to Shenyang Women and Children's Hospital from January 1,2015 to December 30,2021.According to different treatment methods,they were divided into a study group(26 cases,LNG-IUS+metformin)and a control group(26 cases,high efficiency progesterone+metformin).Regularly review endometrial pathology and analyze the differences in complete remission rate,recurrence rate,and pregnancy outcomes between the two groups.Univariate Logistic regression was used to analyze the factors affecting complete remission,recurrence,and pregnancy outcomes in those patients.Results:There was no statistically significant difference in general clinical data between the two groups(P＞0.05).Compared with the control group,the study group had higher complete remission rate,shorter average complete remission time,less recurrence rate,and higher live birth rate,with a statistically significant be-tween the two groups(P＜0.05).Logistic regression analysis found that body mass index(BMI)≥30 kg/m2was a risk factor for complete remission(P＜0.05);BMI ≥30 kg/m2 and patients with diabetes or insulin resistance were the risk factors for recurrence after treatment(P＜0.05);BMI≥30 kg/m2 and diseases associated with fe-male reproductive system were the risk factors for pregnancy after preserving fertility therapy(P＜0.05).Conclu-sions:LNG-IUS combined with metformin has a more satisfactory therapeutic effect and pregnancy outcomes,compared to high efficiency progesterone combined with metformin in preserving fertility therapy.At the same time,BMI＜30 kg/m2 can increase the complete remission rate,reduce the recurrence rate after cure,and in-crease the pregnancy rate after preserving fertility therapy.

Objective:To investigate the therapeutic effectiveness and related factors of fertility preservation therapy(referred to as conservation therapy)using Levonorgestre-releasing intrauterine system(LNG-IUS)com-bined with Metformin in patients with atypical endometrial hyperplasia and early endometrial cancer.Methods:A retrospective analysis was conducted on the clinical data of 41 patients with atypical endometrial hyperplasia and 11 patients with early endometrial cancer who required fertility preservation therapy and admitted to Shenyang Women and Children's Hospital from January 1,2015 to December 30,2021.According to different treatment methods,they were divided into a study group(26 cases,LNG-IUS+metformin)and a control group(26 cases,high efficiency progesterone+metformin).Regularly review endometrial pathology and analyze the differences in complete remission rate,recurrence rate,and pregnancy outcomes between the two groups.Univariate Logistic regression was used to analyze the factors affecting complete remission,recurrence,and pregnancy outcomes in those patients.Results:There was no statistically significant difference in general clinical data between the two groups(P＞0.05).Compared with the control group,the study group had higher complete remission rate,shorter average complete remission time,less recurrence rate,and higher live birth rate,with a statistically significant be-tween the two groups(P＜0.05).Logistic regression analysis found that body mass index(BMI)≥30 kg/m2was a risk factor for complete remission(P＜0.05);BMI ≥30 kg/m2 and patients with diabetes or insulin resistance were the risk factors for recurrence after treatment(P＜0.05);BMI≥30 kg/m2 and diseases associated with fe-male reproductive system were the risk factors for pregnancy after preserving fertility therapy(P＜0.05).Conclu-sions:LNG-IUS combined with metformin has a more satisfactory therapeutic effect and pregnancy outcomes,compared to high efficiency progesterone combined with metformin in preserving fertility therapy.At the same time,BMI＜30 kg/m2 can increase the complete remission rate,reduce the recurrence rate after cure,and in-crease the pregnancy rate after preserving fertility therapy.

Objective:To investigate the therapeutic effectiveness and related factors of fertility preservation therapy(referred to as conservation therapy)using Levonorgestre-releasing intrauterine system(LNG-IUS)com-bined with Metformin in patients with atypical endometrial hyperplasia and early endometrial cancer.Methods:A retrospective analysis was conducted on the clinical data of 41 patients with atypical endometrial hyperplasia and 11 patients with early endometrial cancer who required fertility preservation therapy and admitted to Shenyang Women and Children's Hospital from January 1,2015 to December 30,2021.According to different treatment methods,they were divided into a study group(26 cases,LNG-IUS+metformin)and a control group(26 cases,high efficiency progesterone+metformin).Regularly review endometrial pathology and analyze the differences in complete remission rate,recurrence rate,and pregnancy outcomes between the two groups.Univariate Logistic regression was used to analyze the factors affecting complete remission,recurrence,and pregnancy outcomes in those patients.Results:There was no statistically significant difference in general clinical data between the two groups(P＞0.05).Compared with the control group,the study group had higher complete remission rate,shorter average complete remission time,less recurrence rate,and higher live birth rate,with a statistically significant be-tween the two groups(P＜0.05).Logistic regression analysis found that body mass index(BMI)≥30 kg/m2was a risk factor for complete remission(P＜0.05);BMI ≥30 kg/m2 and patients with diabetes or insulin resistance were the risk factors for recurrence after treatment(P＜0.05);BMI≥30 kg/m2 and diseases associated with fe-male reproductive system were the risk factors for pregnancy after preserving fertility therapy(P＜0.05).Conclu-sions:LNG-IUS combined with metformin has a more satisfactory therapeutic effect and pregnancy outcomes,compared to high efficiency progesterone combined with metformin in preserving fertility therapy.At the same time,BMI＜30 kg/m2 can increase the complete remission rate,reduce the recurrence rate after cure,and in-crease the pregnancy rate after preserving fertility therapy.

Objective:To investigate the therapeutic effectiveness and related factors of fertility preservation therapy(referred to as conservation therapy)using Levonorgestre-releasing intrauterine system(LNG-IUS)com-bined with Metformin in patients with atypical endometrial hyperplasia and early endometrial cancer.Methods:A retrospective analysis was conducted on the clinical data of 41 patients with atypical endometrial hyperplasia and 11 patients with early endometrial cancer who required fertility preservation therapy and admitted to Shenyang Women and Children's Hospital from January 1,2015 to December 30,2021.According to different treatment methods,they were divided into a study group(26 cases,LNG-IUS+metformin)and a control group(26 cases,high efficiency progesterone+metformin).Regularly review endometrial pathology and analyze the differences in complete remission rate,recurrence rate,and pregnancy outcomes between the two groups.Univariate Logistic regression was used to analyze the factors affecting complete remission,recurrence,and pregnancy outcomes in those patients.Results:There was no statistically significant difference in general clinical data between the two groups(P＞0.05).Compared with the control group,the study group had higher complete remission rate,shorter average complete remission time,less recurrence rate,and higher live birth rate,with a statistically significant be-tween the two groups(P＜0.05).Logistic regression analysis found that body mass index(BMI)≥30 kg/m2was a risk factor for complete remission(P＜0.05);BMI ≥30 kg/m2 and patients with diabetes or insulin resistance were the risk factors for recurrence after treatment(P＜0.05);BMI≥30 kg/m2 and diseases associated with fe-male reproductive system were the risk factors for pregnancy after preserving fertility therapy(P＜0.05).Conclu-sions:LNG-IUS combined with metformin has a more satisfactory therapeutic effect and pregnancy outcomes,compared to high efficiency progesterone combined with metformin in preserving fertility therapy.At the same time,BMI＜30 kg/m2 can increase the complete remission rate,reduce the recurrence rate after cure,and in-crease the pregnancy rate after preserving fertility therapy.

ObjectiveA rapid enrichment and detection method for Escherichia coli O157∶H7 was developed by using multienzyme isothermal rapid amplification （MIRA） fluorescence method combined with metal organic frameworks immunomagnetic beads. MethodsUsing rfbE gene as the target， the primers， probes and reaction system were screened， and the specificity， sensitivity and practical application of this method were investigated. ResultsThe detection limit of Escherichia coli O157∶H7 was 1.18×10⁵ CFU‧mL^-1， and the detection limit of DNA concentration was 9 pg‧μL^-1. The detection process was completed in 20 minutes. The test results of 47 strains （24 target strains and 23 non-target strains） were consistent with real-time PCR （RT-PCR）. ConclusionA method based on metal-organic framework immunomagnetic beads enrichment combined with MIRA assay is developed in this study. The method is simple， rapid and suitable for rapid enrichment and detection of Escherichia coli O157∶H7 in food.